Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 31, 2007

Polydex’ Shares Plunge 50% with Halt of HIV Trial

  • CONRAD, a reproductive health research organization, halted a Phase III trial of Polydex Pharmaceuticals’ candidate for HIV prevention in women as it seemed to instead increase the risk of HIV. Ushercell, a cellulose sulfate-based topical microbicide gel, was being tested in women and trials were underway in South Africa, Benin, Uganda, and India.

    The company opened traded at $3.18, representing a 52.25% drop in price.

    "Ushercell has shown a consistent safety profile up to this point, having undergone 11 rigorous clinical safety and contraceptive trials involving more than 500 participants before entering the HIV prevention trial," states Polydex president and CEO, George Usher. "CONRAD will continue to evaluate the findings to help us determine the biological cause of an increased sero-conversion rate detected in the preliminary analysis at some of the trial sites."

    Simultaneously, Family Health International (FHI) stopped a second Phase III cellulose sulfate trial in Nigeria. Although the FHI trial did not detect an increased HIV risk associated with cellulose sulfate, the decision was made as a precautionary measure, given CONRAD trial data.

    Cellulose sulfate was one of four microbicides currently in effectiveness trials for prevention of HIV and other sexually transmitted infections. At this point, it is not clear why use of cellulose sulfate was associated with an increased risk of HIV infection in the CONRAD trial.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »